Imagen
- Company typePrivate
- Founded2015
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
Imagen firmographics
Firmographics- Name
- Imagen
- Legal name
- Imagen Technologies, Inc.
- Website
- https://imagen.ai
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Where Imagen is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Imagen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Diagnostics as a Service (DaaS): Comprehensive platform providing imaging equipment, technical staff, radiologists, imaging software, and proprietary FDA-cleared AI devices bundled together. No upfront costs to practices. Revenue generated through service delivery to provider organizations.
- In-Clinic Imaging Services: Permanent, in-office imaging equipment and programs with end-to-end support including interpretation by board-certified specialists augmented by AI.
- AI-Enabled Specialist Interpretations: U.S.-based, sub-specialized clinician interpretations enabled with cutting-edge AI for improved accuracy, consistency, and timeliness.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing based on organizational needs |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Imagen product offering
Product offeringCore offering
Imagen operates a Diagnostics as a Service (DaaS) platform that delivers AI-enabled diagnostic imaging to healthcare providers. The company bundles FDA-cleared deep-learning AI software, sub-specialized radiologist interpretations, in-office imaging equipment, technical staffing, and program support into a single offering delivered to independent practices, hospitals, and health systems with no upfront capital costs. Its portfolio of FDA-cleared AI devices (OsteoDetect, FractureDetect, ChestCAD, Aorta-CAD, Lung-CAD) targets fracture detection, chest X-ray abnormalities, aortic findings, and pulmonary conditions.
Differentiator
Problem solved
Functional benefit
Brands
- RadGap: AI-enabled image and report analytics service that helps payers, providers, and other RBEs close care gaps
- OsteoDetect
- FractureDetect
- ChestCAD
- Aorta-CAD
- Lung-CAD
Products and services
- OsteoDetect First-ever FDA-cleared software device for Radiological Computer Aided Detection (CADe) that uses AI to detect and localize distal radius fractures—the most commonly misdiagnosed musculoskeletal injury. In clinical study, clinicians experienced a 47% relative reduction in misinterpretation rate when aided by the software. Sold to healthcare provider organizations.
- FractureDetect AI-enabled fracture detection software that detects hard-to-spot fractures throughout the musculoskeletal system across multiple X-ray views. Clinicians showed a 45% relative reduction in missed fractures when assisted by the software in clinical study. Sold to healthcare provider organizations.
- ChestCAD AI software that detects, categorizes, and localizes suspicious regions on chest X-rays, trained on a proprietary dataset with labels comprehensively encompassing all abnormalities that can be screened for on a chest X-ray. Clinical study showed a 40% reduction in errors. Sold to healthcare provider organizations.
- Aorta-CAD Cloud-based, software-only medical device using deep learning to detect and highlight findings associated with Aortic Atherosclerosis and Aortic Ectasia on chest X-rays. Physicians showed a 62% relative reduction in misses for aortic calcification and 35% reduction for dilated aorta when assisted. Sold to healthcare provider organizations.
- Lung-CAD AI software that detects and highlights radiographic findings of interstitial thickening and lung hyperinflation, suggestive of Pulmonary Fibrosis and COPD. Physicians showed a 48% relative reduction in misses of interstitial thickening and 40% reduction in lung hyperinflation when assisted. Sold to healthcare provider organizations.
- RadGap AI-enabled image and report analytics service that helps payers, providers, and other risk-bearing entities (RBEs) close care gaps by identifying suspected care gaps and documentation errors across key conditions. Powered by computer vision AI, advanced NLP, and market-wide imaging access. Sold to payers, providers, and RBEs.
- In-Clinic Imaging Permanent, in-office diagnostic imaging services with equipment, technical staffing, remote reads, accreditation support, EMR integration, and IT services embedded into existing provider workflows. Includes X-ray, mammography, ultrasound, echocardiography, CT, bone densitometry, spirometry, and more. Delivered to independent practices, hospitals, and health systems with no upfront capital costs.
- AI-Enabled Specialist Interpretations U.S.-based, fellowship-trained, sub-specialized clinician interpretations enabled with FDA-cleared AI for improved accuracy, consistency, and timeliness. Features board-certified radiologists, cardiologists, and sub-specialists providing sub-specialized reads with 99.5% on-time turnaround. Sold to provider organizations.
Quantifiable outcome
- 73% reduction in life-threatening clinical misses
- +8 more outcomes
Companies that use Imagen
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Imagen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
Imagen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Top Medical Institutions and Research HospitalscoreImagen has partnered with top medical institutions, including several leading research hospitals, to design AI devices and curate training datasets. These partnerships enable access to diverse, high-quality medical imaging data and clinical expertise.
Scale indicators15 records
Recent moves7 records
Expansion highlights6 records
Imagen competitors and assessment
Company assessmentEmerging players
- Annalise.ai: AI company with broad chest X-ray and CT triage/detection algorithms pursuing enterprise radiology deployments. Overlaps with Imagen's FDA-cleared chest X-ray and multi-modality AI ambitions.
- Riverain Technologies (ClearRead): AI imaging company specializing in chest X-ray and CT image enhancement for earlier detection of lung and thoracic findings. Directly comparable to Imagen's ChestCAD and Lung-CAD products in cleared chest X-ray AI algorithms.
Broad incumbents
- RadNet: One of the largest U.S. outpatient diagnostic imaging networks, operating hundreds of imaging centers and increasingly embedding AI into its workflow. Directly comparable to Imagen's DaaS model of providing imaging services to providers and patients, though at much larger scale and as an incumbent.
- GE HealthCare: Global medical imaging equipment and informatics incumbent (PACS, AI orchestration, Edison platform) that bundles AI into its installed base. Comparable to Imagen as a broad imaging platform player whose offerings compete with Imagen's DaaS and AI capabilities for hospital budgets.
- Philips HealthSuite / Philips Imaging: Major imaging equipment and informatics incumbent offering diagnostic imaging systems, PACS, and AI-driven clinical applications. Competes with Imagen across both the equipment layer of the DaaS model and AI-augmented interpretation.
- Akumin / US Radiology Specialists: U.S. outpatient diagnostic imaging networks providing in-clinic imaging services and teleradiology. Functionally comparable to Imagen's DaaS model of delivering imaging capacity to providers, though operating physical centers rather than embedding AI-native technology.
Direct peers
- Aidoc: AI company offering FDA-cleared deep-learning algorithms for radiology workflow triage and detection across CT and X-ray. Overlaps directly with Imagen's FDA-cleared AI software portfolio and target customer base of hospitals and health systems.
- Viz.ai: AI-powered care coordination and image analysis platform focused on time-sensitive conditions (notably stroke). Comparable to Imagen as a venture-backed, FDA-cleared radiology AI company selling into hospital systems with workflow-integrated software.
- Qure.ai: AI imaging company with multiple FDA-cleared algorithms for chest X-ray, head CT, and lung nodule detection. Competes with Imagen in FDA-cleared chest X-ray AI and shares the enterprise radiology-AI go-to-market.
- Zebra Medical Vision (Nanox AI): AI imaging analytics company (acquired by Nanox) offering FDA-cleared algorithms across multiple imaging modalities. Closely comparable to Imagen in building a portfolio of cleared radiology AI algorithms sold to provider organizations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Customer concentration
Imagen social profiles
Digital presenceImagen compliance and trust
Trust signalCompliance3 records
Imagen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Imagen leadership team
Management profileNumber of profiles
Profiles7 records
Imagen funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Imagen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Imagen
What does Imagen do?
Imagen operates a Diagnostics as a Service (DaaS) platform that delivers AI-enabled diagnostic imaging to healthcare providers. The company bundles FDA-cleared deep-learning AI software, sub-specialized radiologist interpretations, in-office imaging equipment, technical staffing, and program support into a single offering delivered to independent practices, hospitals, and health systems with no upfront capital costs. Its portfolio of FDA-cleared AI devices (OsteoDetect, FractureDetect, ChestCAD, Aorta-CAD, Lung-CAD) targets fracture detection, chest X-ray abnormalities, aortic findings, and pulmonary conditions.
Is Imagen a public or private company?
Imagen is a private company. It is classified as venture growth investor backed and is currently operating.
When was Imagen founded?
Imagen was founded in 2015. It employs 101 to 250 people.
Where is Imagen based?
Imagen is headquartered in New York, United States, in the North America region.
How does Imagen make money?
Three revenue lines are on record. Diagnostics as a Service (DaaS) is the primary driver. The others are in-Clinic Imaging Services and AI-Enabled Specialist Interpretations.
Who are Imagen's main competitors?
Emerging players on record are Annalise.ai and Riverain Technologies (ClearRead). Broad incumbents are RadNet, GE HealthCare, Philips HealthSuite / Philips Imaging and Akumin / US Radiology Specialists. Direct peers are Aidoc, Viz.ai, Qure.ai and Zebra Medical Vision (Nanox AI).
Does Imagen have an API?
No public API is recorded for Imagen.